Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814935 | 0.94 | MAPK1 (0.62) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5818308 | 0.87 | MEN1 (0.53) | MAPK1MEN1KMT2AMAPTCCR5 | |
| SCHEMBL5823977 | 0.82 | MEN1 (0.53) | MAPK1DRD4MEN1KMT2AMAPT | |
| SCHEMBL5805864 | 0.78 | MEN1 (0.44) | MEN1KMT2AMAPTATMTP53 | |
| SCHEMBL5807466 | 0.77 | MAPK1 (0.62) | MAPK1DRD4MEN1KMT2AMAPT | |
| SCHEMBL5813989 | 0.77 | ALDH1A1 (0.50) | MAPK1DRD4MEN1KMT2AMAPT | |
| SCHEMBL5899204 | 0.76 | DRD4 (0.57) | DRD4MAPTALDH1A1TP53THRB | |
| SCHEMBL5899201 | 0.74 | MEN1 (0.63) | MAPK1DRD4MEN1KMT2ACCR5 | |
| SCHEMBL5899226 | 0.71 | HTR1A (0.79) | — | |
| SCHEMBL5814914 | 0.70 | HTR1A (0.75) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | MAPK1 524/4885DRD4 367/4885MEN1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.